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Abstract 
Purpose: To evaluate the presence of pain in patients diagnosed with severe cerebral palsy (CP) 
according to the degree of motor function impairment.  
Methods: A cross-sectional study was conducted on students of the Association of Parents and Friends 
of Exceptional Children (APAE) diagnosed with cerebral palsy and with severe locomotor disability 
(GMFCS levels IV and V). The study included students of both genders and of any age. After signing 
the consent form, a structured questionnaire was administered to parents or caregivers to collect data 
on the history of the illness and the Paediatric Pain Profile (PPP). A score ≥ 14 out of a possible 60 
points suggests the presence of pain.  
Results: A total of 93 subjects were evaluated. Of the 44 subjects classified with GMFCS level IV, 12 
(21.4 %) suffer pain and among the 49 subjects classified with level V, 44 (78.6 %) had pain symptoms 
(ICDDN ≥ 14, PR = 3.29, 95 % CI 2.01 - 5.38, p < 0.01).  
Conclusion: The results show that pain is prevalent in individuals with severe CP. Furthermore, it is 
more prevalent in patients with a higher degree of locomotor impairment (GMFCS – level V). 
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Cerebral palsy (CP) is defined as a permanent 
disorder of movement and posture due to a non-
progressive brain defect or lesion early in life. 
Considered as the most common form of 
physical impairment in the pediatric age group 
[1], the disorder has a high prevalence, affecting 
approximately 4 out of 1,000 children born alive 
in developed countries [2]. 
 
Regarding the etiology, there is still no 
determining factor for the occurrence of CP. 
However, the conditions that contribute most to 
its occurrence are hypoxemia and ischemia due 
to endogenous or exogenous factors, such as 
genetic and chromosomal abnormalities, 
complications during pregnancy or childbirth, 
infections, parasitoses, among others. 
Depending on the level, there may be impairment 
of cerebral neurological development. As a 
consequence, cognitive development is limited 
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and does not accompany chronological age, 
reflecting a poor quality of life over time [3-6]. 
 
The clinical condition of the patient with CP may 
progress to the development of muscle 
contractures and musculoskeletal manifestations 
such as hip subluxations/dislocations, joint and 
spinal disorders, bone deformities, osteopenia, 
osteoporosis, esophagitis, gastroesophageal 
reflux, recurrent infections, otitis and convulsions 
[3,7].  
 
The use of instruments for assessment and 
classification of patients with CP is very 
important for planning clinical interventions 
aimed at improving the quality of life of these 
patients [3,8]. The Gross Motor Function 
Classification System (GMFCS), which uses 
patients’ locomotion as a parameter, classifies 
the patients affected by CP according to their 
functional independence [9]. This instrument 
uses a five-level ordinal scale to determine, in 
descending order, the level of independence and 
functionality of individuals with CP. The 
impairment levels of individuals classified as 
levels I and II by GMFCS are considered as mild, 
those of level III, as moderate, and those of 
levels IV and V, have their functional impairment 
classified as severe [10,11]. 
 
In addition to the functional impairment 
presented by CP patients, pain, caused by the 
progression of clinical conditions in these 
patients, is a prevalent subjective symptom, 
lasting at least 9 h per week, in approximately 50 
% of the cases. In the patient, this symptom can 
result in changes in behavior, appetite, sleep 
patterns, ambulation, leisure and mood. 
Therefore, it is important to detect pain to treat 
this symptom adequately [5]. Although self-report 
is considered the gold standard method for 
assessing subjective states, individuals with CP, 
because they have limitations in communication 
skills, depend on the reports of parents or 
caregivers and assessment instruments to detect 
pain [12]. 
 
Currently, the Paediatric Pain Profile (PPP) is 
applied to assess pain in children with severe CP 
[12]. PPP was recently adapted and cross-
culturally validated for Portuguese [13] under the 
name of Inventário de Comportamentos da Dor 
na Deficiência Neurológica (ICDDN). Although 
this instrument was developed for the 
classification of pain in children, it is known that 
currently the ICDDN can be used for 
classification of pain in individuals with CP of all 
ages. The literature demonstrates that, because 
the lesion that causes CP is non-progressive, the 
patient remains at the same level of classification 
over the years, which also makes ICDDN a 
useful tool for the classification of pain in adults 
[13,14].The ICDDN is a questionnaire, answered 
by parents and caregivers, consisting of twenty 
items that describe pain-related behaviors in 
patients. Each item was evaluated using a scale, 
in which the sum of scores ≥ 14 suggests the 
presence of pain, providing subsidies for 
planning clinical interventions aimed at the relief 
of this symptom in patients [13]. 
 
Clinical practice suggests an association 
between the degree of functional impairment and 
the intensity of painful symptoms presented by 
patients with CP. However, although valid and 
reliable instruments for assessment of these 
parameters are available, studies on the 
presence of pain and the correlation of this 
symptom with the degree of functional 
impairment presented by these patients are still 
scarce. As far as we know, only the study 
conducted by McKearnan et al [15] which report 
events related to the presence of pain in children 
with CP. Nevertheless, the occurrence of pain in 
patients with CP presenting impairment of motor 
function, regardless of age, has not been 
investigated. 
 
This study evaluated the presence of pain in 
patients with a diagnosis of severe CP according 




Study design and subjects 
 
This observational cross-sectional study was 
conducted following approved by Research 
Ethics Committee of the University of Southern 
Santa Catarina (ref no. 25088313.4.0000.5369 - 
CAI/CEP/UNISUL 491.102) and are in 
accordance with the recommendations of the 
International Ethical Guidelines by the Council for 
International Organizations of Medical Sciences 
(CIOMS/2016) [16]. It was conducted at the 
Association of Parents and Friends of 
Exceptional Children widely known by the 
acronym APAE in Brazil) of the cities of Tubarão 
and Orleans, State of Santa Catarina, Brazil, 
over a six-month period (April to October, 2014). 
After permission was obtained from the relevant 
authority at the EPFA, all the patients with a 
diagnosis of CP were identified. They were then 
classified according to the GMFCS scale. 
Patients with severe locomotor impairment, 
classified as GMFCS levels IV and V regardless 
of gender and age, were selected for this study. 
Excluded were patients with diagnosis of severe 
CP, those whose parents or caregivers did could 
not understand the content of the consent form 
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and hence unable to respond adequately to the 
questions asked by the researchers, or those 
who did not agree to participate in the study. 
 
The parents or caregivers of the selected 
patients signed the consent form to participate in 
the study and a structured questionnaire was 
applied to each by the authors, in an interview to 
obtain demographic information and the 
conditions presented by the patient.  
 
The information obtained included: gender, age, 
pre-, peri- and post-natal history, history of 
surgical procedures and previous hospitalization, 
presence of gastroesophageal reflux, 
pathological postural deviations, other 
pathological conditions, use of medications, 
personal care skills, and verbal communication 
skills appropriate for the age. Information was 
also obtained regarding the presence of pain in 




The data were subjected to statistical analysis 
using Epi-info 3.5.2®software. Results were 
expressed as absolute numbers, proportions, 
means and standard deviations. The variables 
were compared between groups using the Chi-
square test for categorical variables, Student’s t-
test and one-way analysis of variance (ANOVA) 
followed by Bonferroni test whenever 
appropriate. P < 0.05 was considered as 






A total of 93 patients with severe CP participated 
in the study 52 (55.9 %) were male while 41 
(44.1 %) were female 44 patients in level IV and 
49 classified in level V, according to the GMFCS. 
The average age of the patients was 23 years in 
the range of 1 to 57 years with 53.8 % of patients 
aged > 18 years. 
 
Characteristics of pre-, peri- and post-natal 
periods  
 
With respect to the history of the period prior to 
birth, 54 (58.1 %) patients had regular prenatal 
follow-up. 57 (61.2 %) patient of the total 
presented some complication during their 
development in pregnancy, including 
hemorrhage (35 %), prolonged expulsive period 
(21 %) and premature rupture of the membrane 
associated with preterm labor (15 %), which were 
the main gestational intercurrences observed. 
 
Considering the type of delivery, 26.9 % of the 
patients studied were born by cesarean delivery. 
23.7 % were born by vaginal delivery at home, 
11.8 % were born by vaginal delivery at the 
hospital level using forceps, and 37.6 % were 
born by vaginal delivery at the hospital level 
without the use of forceps. The mean gestational 
time was 37 ± 3.38 weeks. 
 
The mean Apgar scores at the first and fifth 
minutes were 5.9 ± 2.23 and 6.6 ± 1.47 points, 
respectively, being considered intermediate [17]. 
Mean birth weight was 2.559 ± 1.063 g. Most of 
the patients (64.8 %) presented normal weight 
and 35.2 % presented low birth weight (< 2,500 
g). Neonatal complications were reported in 85 
patients (91.4 %), with neonatal hypoxia/perinatal 
anoxia described for 60 patients (70 %). The 
mean age at which CP-related symptoms 
appeared was 10.8 ± 2.61 months. 
 
It was shown that 87 of the patients (93.5 %) 
were admitted to the Intensive Care Unit and 44 
(47.3 %) were submitted to a surgical procedure. 
Among other comorbidities, the prevalence of 
epilepsy was observed in 76 patients (81.7 %). 
Of the 93 patients evaluated, 56 (60.21 %) 
presented behaviors suggestive of pain (ICDDN 
≥ 14), 12 (27.3 %) of them were classified as 
level IV and 44 (89.7 %) as level V, according to 
GMFCS (Table 2). 
 
In relation to the use of medication, 80 (86 %) 
patients used medication therapy, and 
anticonvulsants represented the main class of 
medication used (76 %). Among other drug 
treatments, 51 (62 %) patients used gastric 
protector and 48 (59 %) patients used some 
drugs with sedative action. No therapy with direct 
or specific analgesic property was found. 
 
Considering personal care skills, 68 (73.1 %) 
patients were unable to maintain personal 
hygiene independently and none of them had 
adequate verbal communication skills for the 
age. 
 
Demographic characteristics and clinical 
conditions of patients with severe cerebral 
palsy 
 
Among the demographic variables evaluated 
(Table 1), the age and sex of the patients had no 
significant association with the occurrence of 
pain (data not shown). 
 
However, the higher degree of locomotor 
impairment (GMFCS - level V) indicated the 
presence of behaviors suggestive of pain 
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(ICDDN ≥ 14) in patients with severe CP (PR = 
3.29, 95 % CI 2.01 - 5.38, p <0.01; Table 2). 
 
Table 1: Presence of behaviors suggestive of pain 
(ICDDN ≥ 14) detected in patients with severe cerebral 
palsy (CP) according to demographic characteristics 
 
Variable Presence of behaviors 
suggestive  
of pain (ICDDN ≥ 14) 
Age < 18                          62 % 
Age ≥ 18 58.1 % 
Female 70.7 % 
Male 51.9 % 
ICDDN = Inventory of Pain Behaviors in Neurological 
Disability 
 
Furthermore, a greater presence of symptoms 
suggestive of pain (ICDDN ≥ 14) was observed  
in the patients with clinical conditions such as 
postural deviation (PR = 2.13, 95 % CI 1.08 - 
4.22, p < 0.01), hip dislocation (PR = 1.9121, 
95% CI 1.39 - 2.62, p < 0.01), snoring (PR = 
4.4767, 95 % CI 0.72–27.67, p < 0.01), difficulty 
in swallowing (PR = 7.39, IC 95% 1.97 - 27.74, p 
< 0.01), gastroesophageal reflux disease (PR = 
2.2831, 95 % CI 1.14 - 4.53, p = 0.01) and 





The main data of this study showed that pain is a 
prevalent symptom in individuals with severe CP 
and evidence shows that the presence of pain 
was more prevalent in the patients with a higher 
degree of locomotor impairment (GMFCS – level 
V). 
 
The prevalence of male individuals with severe 
CP is in agreement with that found by Chagas et 
al and Cotter et al [8,17]. However, although 
there was a higher number of males among the 
individuals with CP, it was observed that the 
gender of individuals had no influence on the 
presence of pain in these patients. Likewise, the 
age of the patient also had no influence on the 
prevalence of this symptom. As observed, only a 
small percentage of the evaluated patients were 
born preterm. The literature shows that, despite 
the vulnerability of the premature newborn, 
prematurity is not essential for the occurrence of 
CP [1]. The data corroborate previous findings 
that CP presents a high prevalence in term 
newborns, with the main cause being perinatal 
hypoxia/anoxia, which is responsible for the 
largest contingent of cerebral impairment, 
reflected in a low Apgar score presented by the 
newborn [1,5]. 
 
Most patients studied herein were born with 
weight classified as normal. Similarly, Surman et 
al [18] showed that individuals with higher birth 
weight developed CP in the most severe form.  
 
These authors indicated that, although the risk of 
CP is higher in individuals with low birth weight, 
there is a clear relationship between the severity 
of motor impairment and the birth weight of the 
patients, with a higher proportion of those born at 
the ideal weight or greater being more severely 
affected. 
 
The median age of symptom onset indicative of 
cerebral palsy in our study was 10.8 months. The 
findings are similar to a study conducted in 
Denmark, which showed that the mean age of 
diagnosis for CP, associated with the onset of 
symptoms   such    as   high    degree   of   motor 
disability, abnormalities on cerebral ultrasound 
and the presence of epilepsy, was around 11 
months of age [19]. As verified in our study and 
reported in other studies, epilepsy is a prevalent 
comorbidity in patients with CP [4,19-21]. 
 
Table 2: Presence of symptoms suggestive of pain (ICDDN ≥ 14) detected in patients with severe cerebral palsy 
(CP) according to degree of motor function impairment (GMFCS IV and V) and clinical conditions presented 
 
Variable Presence of behaviors 
suggestive of pain in % 
(ICDDN ≥ 14) 






3.2900 (2.01 - 5.38) 
 
<0.01 
Bruxism 64.6 1.8076 (0.87 - 3.71) 0.05 
Snoring 64.0 4.4767 (0.72 - 27.67) 0.01 
Postural deviation 67.6 2.1300 (1.08 - 4.22) <0.01 
Gastroesophageal reflux 
disease 
68.5 2.2831 (1.14 - 4.53) 0.01 
Difficulty in swallowing 74.0 7.3900 (1.97 - 27.74) <0.01 
Hip dislocation 85.7 1.9121 (1.39 - 2.62) <0.01 
ICDDN = Paediatric Pain Profile, translated in Portuguese language as: Inventário de Comportamentos da Dor 
na Deficiência Neurológica; GMFCS = Gross Motor Function Classification System; PR = Prevalence ratio; CI = 
95% Confidence interval. *Chi-square test 
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It therefore, justifies the use of anticonvulsants 
by most of the studied population. 
 
Some clinical conditions observed in patients 
with CP can cause pain, which justifies the high 
prevalence of pain found in the patients 
presenting these manifestations. Pain affects 
negatively the quality of life by causing 
discomfort and being an important limiting factor 
CP patients from developing the skills to carryout 
daily activities [12,13,21,22]. Spasticity, for 
example, leads to muscle contractures that can 
be very painful and to compensatory deformities 
such as scoliosis, cyphosis and hip dislocation, 
which result in difficulties in locomotion, 
positioning and, consequently, the pain [23].  
 
Besides spasticity, gastroesophageal reflux 
disease, prevalent in more than 59 % of patients, 
if not treated, can cause pain, in addition to 
recurrent esophagitis and pneumonia [24,25]. 
Oral dysfunctions, in turn, can result in poor bone 
mineralization due a low ingestion of calcium, 
leading to the development of rickets and 
osteomalacia in these patients, whose major 
symptoms are diffuse bone pain and muscle 
weakness. Moreover, in addition to oral 
dysfunction, anticonvulsants, often used by these 
patients, may also favor the decrease in bone 
mineralization [26]. Patients with CP usually 
require hospitalization and are submitted to 
painful diagnostic and therapeutic procedures, 
such as botulinum toxin injections, 
gastrointestinal endoscopies, venoclysis, 
stomatologic treatment and surgical procedures 
[27,28]. 
 
Although individuals classified in level IV and V, 
according to GMFCS, have their functional 
impairment classified as severe, level V 
individuals present a more compromised clinical 
condition because they are even more likely to 
be affected by complications related to CP 
[10,11]. Thus, the association between the higher 
degree of functional impairment and the 
presence of behaviors suggestive of pain in 
these patients, demonstrated for the first time, 
may be related, at least partially, to the clinical 
conditions presented by these patients that lead 
to the development of this symptom. 
 
It is worth noting that even with a high 
prevalence of pain, this symptom is not treated in 
these patients. As observed with regard to the 
use of drugs to relieve this symptom, no 
evaluated patient used drugs with analgesic 
properties. According to data in the literature, the 
use of drugs by CP patients is generally limited 
to the use of anticonvulsants, which was also 
verified in our study [4,20,21]. 
Limitations of the study 
 
The limitations of this study include a low number 
of subjects and the short duration of the study 
which was performed only in a determinate 
region of South Brazil. However, such limitations 
did not make our work unfeasible, since the data 
were accurate and consistent. The effectiveness 
of the research instruments used may encourage 
its application in future studies, carried out in 





The data show that patients with severe CP who 
had the highest degree of locomotor impairment, 
are more likely to present with pain. Thus, these 
patients should be assisted with the objective of 
identifying and treating this symptom, and aiming 
at improved quality of life. For this, GMFCS and 
ICDDN have proven to be effective tools that can 
be used to assess locomotor impairment and 
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